This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk02: Good day and welcome to the Ingersoll Rand Q3 2024 earnings call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you'd like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you'd like to withdraw your question, please press star one again. For operator assistance throughout the call, please press star zero. And finally, I would like to advise all participants that this call is being recorded. Thank you. I'd now like to welcome Matthew Fort, Vice President of Investor Relations, to begin the conference. Matthew, over to you.
spk04: Good morning and welcome to the Ingersoll Rand 2024 Third Quarter Earnings Call. I'm Matthew Fort, Vice President of Investor Relations. And joining me this morning are Vicente Rinal, Chairman and CEO, and Vic Kinney, Chief Financial Officer. We issued our earnings release and presentation yesterday, and we will reference these during the call. Both are available on the investor relations section of our website. In addition, a replay of this conference call will be available later today. Before we start, I want to remind everyone that certain statements on this call are forward-looking in nature and are subject to the risks and uncertainties discussed in our previous SEC filings. Please review the forward-looking statements on slide two for more details. In addition, in today's remarks, we will refer to certain non-GAAP financial measures. You can find a reconciliation of these measures to the most comparable measure calculated and presented in accordance with GAAP in our slide presentation and in our earnings release, both of which are available on the investor relations section of our website. On today's call, we will review our company and segment financial highlights and provide an update to our 2024 guidance. For today's Q&A session, we ask that each caller keep to one question and one follow-up to allow time for other participants. At this time, I will turn the call over to Vicente.
spk11: Thanks, Matthew, and good morning to all. Starting on slide three, our team delivered another strong quarter of results by leveraging our competitive differentiator, IRX. And for that, I want to thank and acknowledge our employees for continuing to think and act like owners. Our strong execution was highlighted by record orders and revenue. over 200 basis points of adjusted EBITDA margin expansion, 9% adjusted EPS growth, and 20% free cash flow margins. And despite the difficult microenvironment, we expect to deliver on our long-term investor day targets of double-digit adjusted EPS growth and strong free cash flow generation in 2024. Turning to slide four, our economic growth engine describes how we deliver durable compounding results. As stated on the right-hand side of the page, Ultimately, the intended outcomes are double-digit earnings growth and strong free cash flow margins. We remain committed to our strategy of delivering over the cycle our long-term investor day targets as outlined on this page. Our unique culture of ownership combined with IRX is our competitive differentiator, which will help drive that long-term value creation. With that in mind, let me provide a brief update on our growth initiatives. On the next slide, We'll start with our inorganic growth initiatives. I am pleased to highlight four transactions that closed this past month, which together are expected to achieve a mid-teens ROIC by year three. Let me walk through these deals. First, APSCO, which is a leader in the design and manufacturing of fluid power systems for mobile transport equipment. This is a great example of strategic market expansion which further strengthens our position in the dry and liquid blower and vacuum markets with energy-efficient, innovative solutions. Next is Bluetech, which expands Ingersoll Rand's technology capabilities, expertise, and aftermarket potential in high-growth, sustainable end markets, including biogas and carbon capture. Continuing on page six, on the left-hand side of the page, we have UT Pumps, which adds new high-pressure pump technology to our portfolio. in end markets including water, wastewater, food, beverage, and life sciences. And finally, next is Penn Valley Pump, which is a leading manufacturer of positive displacement pumps with patented double-disc pump technology for use in the municipal, industrial, chemical, and food industries. On the right-hand side of the page, I would like to highlight that year-to-date, we have already closed on a total of 15 transactions in 2024. and we have far exceeded our analyzed inorganic revenue target, which bodes well as we look towards 2025. In addition, the funnel continues to grow and remains very active with 10 additional transactions currently under LOI, including deals that will fit into our recently created life sciences business. The funnel, including the deals under LOI, are primarily bolt-on in size. Turning to slide seven, I wanted to take a minute and highlight how we're driving organic growth across our digitally connected assets. As we often get asked two questions. First, what do we do with the data we receive on our connected assets? And two, how do we leverage that data to drive additional revenue? And simply stated, our teams are focused on creating a meaningful positive impact for our customers around energy efficiency and uptime. The example on the slide demonstrates the agility with which we operate. We recently gathered 45 employees across seven countries over a period of just two days. The goal was to do a deep dive into real-time connected asset data to unlock new revenue opportunities. The outcome was that we identified over 40 different revenue-generating insights that collectively could translate to over $25 million in incremental revenue, a figure that speaks volumes about the potential of data-driven innovation for our products. As you can see in the middle of the page, we have examples of those insights, and these range from the optimization of energy consumption and maximizing machine uptime. When we empower our people at every level of the organization to think and act like owners, they make us better by defining new customer experiences, improving our ways of working, and bringing innovative thinking to advance our mission of making life better. I will now turn the presentation over to Vic to provide an update on our Q3 financial performance.
spk04: Thanks, Vicente. Starting on slide 8, utilizing our competitive differentiator of IRX, we were able to deliver strong results within the quarter despite the continued challenging macroeconomic environment. Total company orders grew 10% or up 1% organically, finishing largely in line with expectations. Book to bill was 0.97. which is in line with our previous guidance of above one time in the first half and below one time in the second half. Total revenue was up 7% as reported or down 2% organically. Worth noting that we did see some customers pushing out orders due in large part to site readiness and local approvals. However, we have not seen order cancellations nor do we feel that cancellations are a significant risk. The company delivered third quarter adjusted EBITDA of $533 million, a 15% year-over-year improvement, and adjusted EBITDA margins of 28.6%, a 210 basis point year-over-year improvement driven predominantly through gross margin expansion. Adjusted earnings per share was 84 cents for the quarter, which is up 9% compared to the prior year. Free cash flow for the quarter was $374 million, delivering a solid 20% free cash flow margin in the quarter. And total liquidity was $4 billion, with $1.4 billion of cash on hand at quarter end, which demonstrates the strength of our balance sheet. Our continued strength in free cash flow generation will enable us to remain focused on our capital allocation strategy. As Vicente mentioned earlier, we still have 10 additional transactions currently under LOI, and we continue to have momentum in building our M&A funnel. Turning to slide 9, for the total company, on an FX adjusted basis, Q3 orders were up 10% and revenue increased 7%. Total company adjusted EBITDA increased 15% from the prior year. An ITS segment margin increased 190 basis points, reaching a new high of nearly 31%, while the PST segment margin decreased 30 basis points year-over-year, but remains above 30%. Overall, your SOL RAND expanded adjusted EBITDA margins by 210 basis points. And corporate costs came in at $35 million for the quarter due in large part to a year-to-date true-up of management incentive costs. Finally, adjusted EPS for the quarter was up 9% year-over-year to 84 cents per share, including an adjusted tax rate for the quarter of 22.8%. On the next slide, free cash flow for the quarter was $374 million, including CapEx, which totaled $30 million. Total company liquidity now stands at $4 billion based on approximately $1.4 billion of cash and $2.6 billion of availability on our revolving credit facility. Leverage for the quarter was 1.7 turns, which was a 0.8 turn increase year over year and a 0.3 turn improvement sequentially versus Q2. The year over year increase was driven primarily due to the purchase of ILC Dover earlier this year. Specifically within the quarter, cash outflows included $15 million deployed to M&A, as well as $71 million returned to shareholders through $63 million in share repurchases and $8 million for our dividend payment. Our capital allocation strategy remains unchanged, with M&A being our top priority, and we continue to expect M&A to be our primary use of cash as we look ahead. I will now turn the call back to Vicente to discuss our segment results.
spk11: Thanks, Jake. Moving to slide 11, our industrial technologies and service segment deliver solid year-over-year revenue growth of approximately 3% on top of approximately 19% growth in Q3 of last year. Adjusted EBITDA margins finish at a record high of 30.7% with incrementals of over 100%. Adjusted EBITDA margins finish up 190 basis points from the prior year, which was driven primarily by gross margin expansion. Book-to-bill was 0.97 times, with organic orders up low single digits, finishing largely in line with expectations. Moving to the product line highlights, compressor orders were up mid-single digits, and we continue to see positive orders globally, excluding China. Compressor revenue was up low single digits in the quarter, while industrial vacuum and blower orders were up high single digits, and revenue was up low single digits. For innovation in action, we're highlighting our new patented oil-free technology that is focused on high growth, sustainable end markets like food, beverage, and clean energy. This patented technology offers a 30% reduction in total cost of ownership, driving a great return on investment for the customer and helping our customers achieve their scope one and scope two emission reduction targets. Turn to slide 12, the PST segment achieved 3% organic order growth and deliver adjusted EBITDA of approximately $180 million with a margin of 30%. We continue to see many encouraging signs within the PST segment with sequential order growth of 13% and sequential revenue growth of 16%. Book-to-bill was 0.96 or 0.99 on an organic basis. In addition, short cycle orders in PST segments remain positive. with book and ship orders of high single digits year over year, demonstrating the continued ongoing momentum of organic orders driven mainly by our demand generation efforts. We're pleased to see organic order growth stabilizing, and we remain positive about the underlying health of the PST business. Finally, I wanted to highlight the performance of ILC Dover within the quarter. Sequentially, total ILC Dover revenue improved low double digits with the biopharma business up low 20s, and the medical device component business up low double digits. Year over year, revenue for the biopharma business is up double digits. We're very pleased with the business performance, and we're optimistic about the potential to drive above market growth. Our PST innovation in action example shows how our mission critical products can help a community in need. Planet Water Foundation provides safe drinking water access in the wake of emergencies and natural disasters. Using our dosatron pumps, the Planet Water System can provide clean drinking water for up to 6,000 people without the need of electricity. The system was recently deployed in Nashville, North Carolina after Hurricane Helene. I also would like to take a moment to talk about the recent hurricanes, which impacted our Dosatron site in the Tampa area, where several of our team members experienced flooding that damaged many of their homes. And despite this, they worked late nights and weekends to support our customers. So to our Dosatron team, a special thank you for your dedication, hard work, and resiliency. Your actions show what we can achieve with our ownership mindset and culture. On the next slide, let me provide an update on the current market trends as we always get a lot of questions about our leading indicators. Marketing qualified leads, or MQLs, are a key leading indicator of our short to medium cycle business. As illustrated in the chart on the left-hand side of the page, our MQLs continue to grow. For the quarter, organic MQLs are up 12% year-to-year and are up 7% sequentially. As for the longer cycle component of our portfolio, One key indicator we look at is the funnel activity for engineer-to-order compressor systems. And we remain encouraged, as the funnel activity for Q3 is up 22% year over year. Consistent with what we discussed last quarter, the decision-making process remains elongated. The feedback we hear continues to be centered around customer site readiness and too many projects happening at the same time, which is impacting EPC engineering capacity. As we move to slide 14, we have updated our full year 2024 guidance for revenue, adjusted EBITDA, and adjusted EPS. Total company revenue is now expected to grow overall between 5% to 7%, which is down 100 basis points versus our prior guidance. For adjusting, our organic revenue guidance down 200 basis points, driven predominantly by the timing of orders converting into shipments. While we are very encouraged by the improvement in Q3 organic order momentum and continuous strength in market activity, we continue to see customer delivery delays driven largely by customer site readiness and other factors, including the upcoming election. We expect these orders to be delivered in 2025. As we look at our NQL data, loan cycle project funnel, and Q3 organic order growth, This situation remains encouraging as we move into 2025. FX is now expected to be approximately flat for the full year, which is approximately 100 basis points as compared to our previous guide. M&A is projected to contribute around $455 million, which reflects all completed and closed transactions as of October 31, 2024. Corporate cost remains at approximately $170 million. Total adjusted EBITDA for the company is expected to be in the range of $2.01 billion and $2.04 billion, which is approximately 13% year-over-year at the midpoint. Adjusted EPS is projected to be within the range of $3.28 and $3.34, which is up approximately 12% year-over-year at the midpoint. On the bottom right-hand side of the page, we have included a 2024 four-year guidance bridge showing the changes in our latest guidance as compared to our previous guidance provided in August. No changes have been made to our guidance on interest expenses, tax rate, cap expense as a percentage of revenue, and free cash flow to adjusted net income conversion. All remain in line with our previous guidance. Finally, as we turn into slide 15, before we open the call for questions, let me wrap up by saying that I am very pleased with how our teams continue to execute despite the current market conditions. As we look to close out 2024, our teams continue to execute well in terms of targeted share gains and driving momentum in geographies where we have historically been under-penetrated. And despite lower organic growth expected in 2024, We're on track to deliver a nearly 10% organic growth CAGR for the total company over the past four years, which is two times our stated goal. What continues to differentiate Incas-Oran is our economic growth engine, where even in a difficult microenvironment, we're able to add differentiated technologies to the portfolio with a distinct focus in high-growth sustainable air markets. Year-to-date, we have added 15 companies through M&A with 10 more bulk-ton targets under LOI, and we don't see this momentum slowing down. The real power continues to be in the value we're able to unlock as part of this model. We're on track to deliver, again, triple-digit adjusted EBITDA margin expansion through strong initiatives focused on improving gross margins, which translate into strong double-digit earnings growth and solid free cash flow generation. We believe that we have created a durable model that will continue to deliver exceptional financial results, differentiating Incasol REN as a premier growth compiler. With that, I'll turn the call back to the operator to open a call for Q&A.
spk02: If you wish to ask a question, please press star followed by one on your telephone and wait for your name to be announced. We ask that you limit your questions to one-on-one follow-up so we're able to take as many questions as possible. Your first question comes from the line of Mark Hollerand from Baird. Your line is open. Hey, good morning, everyone.
spk09: Morning, Mike. Hey, so let's start on slide 13. And, you know, I certainly heard the prepared remark commentary around project push-outs. But maybe you could put that slide in context to what you're seeing on an underlying basis right now. Um, you know, because I think the is an example that's been improving as you've worked through the year here, but the organic growth guidance has moved down again, partially project push outs, but maybe kind of correlate all those moving pieces because I'm guessing the, the, the is probably a little bit of a shorter term lead time or leading indicator. Excuse me. And so kind of just. Maybe put all that in context and then related. What needs to happen to have that slide sync with the order trends and the underlying demand and the underlying trends in your portfolio?
spk11: Yeah, Mike, I mean, first of all, I'll say that we're definitely encouraged by what we see in terms of that market activity. And I will also categorize the MQL market activity as, as you recall, we always say that's our demand generation engine that we're instigating demand. So basically, this is how we continue to penetrate new customer accounts. We always said that 50% of those MQLs go into customers that have not purchased anything from Ingersoll Run over the past, call it, you know, two years. So it's about how do we continue to take share. Now, clearly, in the past, historically, we said that an MQL will translate into an order over a period of six to eight weeks. But what we're saying now is that that is definitely getting elongated. We're not making a commentary as to how elongated that is, but it is definitely much longer than what historically has been. And a lot of that has to do with kind of what you see in the market. I mean, clearly customer readiness here lately could be some of the election instability or kind of predicting as to what might happen and kind of some of the holdups that not only us, but maybe others are seeing. So I think the encouragement for us is that these are real customers, really interested in real products. I mean, this is not just a customer asking a question. This is now a qualified lead of an activity that the customer is just very interested in putting in a purchase order that is going through our funnel. The good news, too, as well, is that we don't see cancellations. We don't see customers leaving our funnel online. And it's just a matter of continuing to nurture those customers until we get the closure. We have continued to see good close rates. And so that's why we continue to be very encouraged about the activity that we're seeing, that we're generating. And as to the long cycle project, kind of fairly similar in scope. Keep in mind over the past few years, there's been a lot of mega projects that have been announced. And I think you have seen maybe in the market that not a lot of those have translated into the orders. And that has to do because these mega projects, when they get designed, they need to get designed and processed through typically large engineering companies, engineering contracting companies. We call it APCs. And there's just a lot of projects that are going through. What is encouraging is that we're seeing good movement on those. I spent over the past two weeks, I did a lot of travel around the world. I spent actually... an entire weekend in Middle East, in Dubai, and Saudi, just to even talk to customers about specific projects and just to get that perspective firsthand from those customers. And it's very encouraging with what we're seeing. What we're seeing here is that it's just taking longer. But again, that to us bodes well as we continue to look forward. And in the meantime, we'll just continue to execute in control what we can control and deliver the performance that we can deliver.
spk09: So if I take your comments then, you know, the optimism, the fact that these leading indicators are tracking the right way, does that mean that when you think about next year, it starts tracking towards a more normal growth algorithm for the company? And if it doesn't, you know, what do you think prevents you from getting there at this point? Market, timing of these projects, any other variables?
spk11: Yeah, I think, Mike, I think the way we view it is that, I mean, we don't view that the market is going to see a V-shaped recovery. We're going to see that gradual recovery as we go into 2025. And as we always do, we want to kind of see continuation here in the fourth quarter, how everything kind of lays out in preparation for our 2025, and we give guidance on our next earnings call. But the other point that bodes well for us is that, you know, here even in the Q3 period, our backlog actually grew year over year and sequentially. So, again, it kind of continues to bode well as we think about 2025, but we'll be able to provide better color and guidance as we go into our next earnings cycle. Interested. Thank you, Mike.
spk02: Julian Mitchell from Barclays. Your line is open.
spk08: Hi, good morning. Good morning. Maybe just the first question, Vicente, around sort of current demand trend, just flesh that out a little bit more. I think the last quarter it was very clear that China was the big headwind or surprise factor back in the early summer months. And I see your compressor orders, ex-China, are good, but Since the last call, have you seen kind of a broadening out of those project pushouts? Is there maybe weakness in more geographies, perhaps, than just the China factor? And, you know, I understand that orders are good, backlogs are good. It's the conversion of those two things into sales that's sluggish at present. But when we take a step back and look at the overall situation, kind of process industries exposure of ITS. Is it fair to say that those, you know, generally would lag kind of earlier cycle markets? And that speaks to your point on a very gradual recovery pace next year.
spk11: Yeah. No, thanks, Julian. You know, China, back to that commentary about the travel, actually two weeks ago I spent a weekend in China with a team And as I always do, spend a lot of good amount of time with customers. So I can also give you maybe a little bit of color in that too as well. You know, China clearly, the market has been challenged this year and has remained largely, I would say, unchanged as we move through Q3 and into early parts of Q4. You know, I think the good thing, I guess the good point as I spend time with customers and give you maybe a data point of this kind of customer that, It's a very large account. It's a company that has over 400 facilities just in China alone and close to 1,000 facilities across the world. And the tone from this customer was fairly positive towards what we, as Incosur RAN, can do for them around our service-oriented initiatives. I mean, the customer was very enthusiastic on leveraging all the M&A in terms of technologies that we have done across, you know, not only in China, for China, but also in the U.S. and bring technology back to China. to be able to help them, and particularly with the same growth themes and thematics that we say, energy efficiency and how do we continue to improve the operational ability of their facilities. The customer commented incredibly well about our ownership mindset and how they feel that our employees, when they go to their factories, kind of take incredible care of them. And the customer was, I'll say, positive in terms of what they're seeing around investments, not only in China for China, but then now starting to expand outside of China, particularly in countries like even Africa. So I think we see customers are willing to invest and willing to continue to accelerate how they continue to see their efficiencies. In terms of this question, did we see anything broadly across any other regions that inflected negatively. I'll say no for the most part. I mean, I think that the guidance here, as we said, is driven largely by the shipment timing. And this is just the willingness of the customers to take the product now versus, you know, we're saying, hey, you know, we're seeing, we have seen delays and customers getting some of those pushouts. And we're just going to say and assume that this is going to actually now move into 2025, some of them. And that's really the driver of our of our guidance, organic guidance takedown. In terms of your question about the ITS business-driven process industries and how do we traditionally see, you're absolutely right in the sense that we expect to see that gradual movement. I think we view ITS as a very diverse, diverse in nature, and we have said always that we can pivot our products and technologies to the pockets of growth that we may see And clearly, you have seen PMIs that have been in contraction territory for over 24 months. We believe that we have outperformed that. I mean, example, last year, we grew organically a double-digit, and this year will be more flattish. But again, we think it's better than contraction territory that PMIs are showing. But yeah, I mean, having said that, we believe that growth will continue to come more gradually as we expect these PMIs to improve, and we don't expect that V-shaped recovery or kind of snap a growth from one quarter to another, but more gradually.
spk08: That's helpful. Thank you. And just my follow-up on the margin front. So maybe just put a finer point on the sort of EBITDA margin rates in Q4. I think maybe it's down a little bit sequentially, but maybe I have that wrong, but that would be... I know historically you're normally up sequentially in Q4. And as we think about 2025, exceptional incrementals this year, any sort of give back or normalization of incrementals as you think about next year because of investment spend or anything like that?
spk04: Yeah, Julian, this is Beck. Let me take that one. So, you know, I think first and foremost, you know, Frankly, exceptional margin performance by the teams in Q3. Really proud of what the teams were able to deliver. I think it's worth noting that, you know, largely driven by gross margin expansion, and you really are starting to see to the fruits of the labor and things like, you know, recurring revenue and things of that nature that we've been talking about for quite a while. I think as you move to Q4, you know, I think sequentially, you know, you're still going to see essentially two segments that are in the 30% EBITDA margin range. It's probably the easiest way to say it. I think corporate costs will probably normalize a little bit in that 40 to $45 million range. And so that's kind of the way to think about that margin algorithm for Q4. Now, I think as you've always seen us, uh do and say you know we're going to continue to make the requisite investments uh for ongoing growth and if there's room to probably outperform on the margin front specifically in its i think you've seen us do that for several quarters um you know i don't think you'll hopefully see anything necessarily different in q4 but you know we think around 30 is probably the right levels as you think about q4 specifically To your question about 2025, and obviously not giving necessarily guidance at this point, but is there anything that we would say is, quote unquote, giving back margins or anything of that nature? No, I don't think that that's the way to think about it. We think that next year will be a bit of a normal margin expansion kind of in line with what we've historically laid out. But we feel really good about where we are. And most importantly, we continue to make the right investments in areas like innovation, demand generation, and commercial resources.
spk02: Great. Thank you. Your next question comes from vertical research partners. Your line is open.
spk05: Thank you. Good morning, everyone. Just kind of back to the project delays and uncertainty, you know, what you said about the EPCs is interesting. But, you know, a lot of companies are pointing to election uncertainty. What is your view on that? Is that a reality or an excuse? And you see, you know, the outcome impacting your business substantially one way or the other, or just having an outcome and getting this over with, you know, just lift some uncertainty. We can kind of try to move on with whatever hand we're dealt.
spk11: Yeah. You know, it's interesting. I mean, the reason why we don't call it out too often is because it is – we do a lot of voice of customers, and we are pretty close and intimate to them as they go through their buying cycle. And it doesn't come off top of the table or top of the chart in terms of as the reason why the elongation. Now, naturally, as we have been kind of getting closer to the election here, has it been more – verbally said more often, I'll say yes. It is definitely not the top of the list, but it is definitely mentioned more often. So I think there's a little bit of that. I mean, how big of a reality it is or how much pent-up demand is going to be after the election kind of snaps or kind of is over with and we see a better outcome, I think still a lot to be determined based on clearly what happens at the election time. But again, we will remain focused on controlling what we can control, and that's our play basically here, Jeff. So to answer your question, yeah, have we heard that a little bit more often? I would say maybe yes, but it is definitely not the number one reason for the elongation.
spk05: Do the project delays, though, skew to the U.S.? It sounds like it's actually just quite global.
spk11: It is quite global, Jeff, yeah, very global. That's why the election is definitely not the only reason, to be honest. Saudi Arabia and spend time with customers, it is probably delayed because of site readiness and EPC. I mean, it's basically those two.
spk05: Yeah. And just pivoting real quick, just mix, obviously, or seemingly would be positive, given equipment, software, and Vic just mentioned service. Can you just maybe give us a little bit of an update on how service is performing, sort of what the growth rate is, how you expect to close out 2024 on the service side?
spk11: Yeah, very encouraging on the service side. Service positive, good momentum that we saw clearly organically in the quarter. And I think everything that we said at the investors' day is working really well. The recurrent revenue and the focus that the teams are giving it And not just, I mean, the U.S. is one of the biggest tensions that we have, but how we see now the momentum in Europe and even also in China and India. India was the other country that I spent a lot of time with the team. And again, that service-oriented, it's a great solution that not only our teams are launching, but also customers, they really want. So I'll say, yep, it's good. Good momentum that we're seeing.
spk05: All right. Thank you.
spk02: Your next question comes from the line of Rob Weidemeyer from Milius Research. Your line is open.
spk07: Yeah, hi. Thanks for the question. You know, your margin performance continues to be extraordinary, and I'm a little bit curious just about how much opportunity lies ahead. Maybe we do ITS versus behind. Do you still see as much potential there if you're, you know, shaping your workflows to be more growth-oriented than margin-oriented? Just maybe comment that, because obviously you've done amazing things in the last couple of years.
spk11: Yeah, Rob, I'll say, you know, internally, I'll start with the last question. Internally, we like to say the power of the end. It's about growth and margin. So we always look at the quality of earnings, and we look at making sure that, yes, we're growing, but that we're growing profitably. So I'll say that we go for both. Yes, I mean, year-to-date, we've seen exceptional incrementals, and that speaks to, as Vic said, you know, the gross margin activities that we have done, despite the market volatility, we continue to make a lot of investments. Investments not only around, you know, recurring revenue streams and things like that, also new product technology. Part of my trip here in Asia, spent a full day with the team in China, specifically on innovation. And I think the innovative solutions that the team has developed are very unique and very exciting. to see and things that we're leveraging now also from a global basis. So the example that we put out here in terms of the code-a-thon that will definitely drive some incremental revenue to us as well, that's also part of our investment. So I'll say we continue to be positive about where we have margin expansion here in IPS.
spk04: And, Rob, maybe I'll just add maybe to your question about, you know, To Vicente's point, I think we've been incredibly pleased with the momentum we've seen in 24. We're poised for another triple-digit margin expansion year, and as the guidance implies and as you've seen, largely led on the ITS side. I think as we flash forward, it's kind of back to kind of how we laid things out. We expect that there still is opportunity in ITS. Are you going to see the pace probably as much in ITS as you've seen historically? maybe not as much. I think there's still opportunity there, but I do think there's probably a little bit more outsized opportunity in PST. And that very much fits with our, you know, stated investor day targets of how to get that to a closer to a mid thirties EBITDA margin. So I'm still really pleased. And I think that, you know, we see a lot, you know, a lot of great opportunity as we now think about the PST business and particularly also with the, you know, the ILT Dover business now being, you know, fully integrated.
spk07: Okay. I'll stop there. Thank you.
spk02: Your next question comes from the line of Andy Kapowitz from Citigroup. Your line is open.
spk00: Good morning, everyone. Good morning, Andy. Vicente, can you talk about or give us more color about the acquisition landscape as you start to think about 25? You've obviously been very active, as you said, for 24. Your LOIs, I think, went up a little bit sequentially. So do you see 25 as potentially as robust a year for incremental M&A activities 24? And I know you said... yellow isomer bolt-on in nature, is that generally the type of activity that you would expect in 2025?
spk11: Yeah, Andy, I'll say the answer, the simple answer to that is yes. I mean, we definitely see, we're seeing a lot of good activity. Clearly, you heard on the opening remarks too as well with ILC Dover acquisition that gave us a $10 billion expansion into an addressable market, and that comes in with looking in terms of bolt-on And we already have a few of those in our funnel. So, yes, I mean, 2025, I'll say it looks to be, you know, still also very encouraging as we see the momentum that we have today. Yes.
spk00: Okay. You mentioned in PST book and ships still up high single digits. You mentioned sequential orders up 13%. I know organic revenue growth has been stubbornly negative for a while now in that segment. So does a better order environment suggest that you do have relatively good visibility to improve growth in 25? Maybe just on ILC Dover in particular, a lot of positive commentary on it, but just an update there.
spk04: Yeah, Andy, this is Vic. Maybe I'll start and I'll let Vicente add in. You know, I think with regards to just kind of the base PST business, and we'll kind of comment on ILC Dover separately, you know, we've been very encouraged by the positive orders momentum that you've seen now for a few quarters. You know, we are starting to see that translate, you know, a bit better. We do expect that, for example, in Q4 to be part of that growth algorithm, specifically as part of our Q4 guidance as you kind of get to the full year guide. Um, you know, we'll, we'll, we'll pause on necessarily 2025 commentary, but I think the good news here is, you know, a combination of both the base business, as well as a lot of the acquisitions, which have now really been fully integrated. Um, I think positions as well, as we move into 2025 and we're encouraged by kind of what I'll say, the base PST business.
spk11: And listen, they may let you come up. And then on the, on the ILC, I'll say, I'll say that the integration continues to go very well. You saw some of the numbers in terms of biopharma and the medical device component business are doing really well. And I think the most important piece is that we continue to make investments for growth in the ILC dover already as we see opportunities to accelerate growth in both the biopharma and the medical device business. And investments are not only just on demand generation, target commercial, and innovation of product investment, but also investments in talent. We have multiple new general managers. I think we said before we structure the business now into three distinct P&Ls with new general managers in the P&Ls, and we're reinforcing the functional support area. So we're making a lot of the good prerequisite investments to scale that up and scale that business as we move forward.
spk00: Appreciate the call, guys.
spk02: Thank you. Your next question comes from the line of Nigel Coe from Wolf Research.
spk01: Your line is open. Thanks. Good morning, everyone. Morning. Just wondering if we could maybe just hone in on the PST sort of outlook for 4Q. It looks like we're sort of pointing towards a return to growth in the fourth quarter, obviously complicated and easier. Just wanted to make sure that's the case. And then I just want to just try and nail this M&A contribution. You definitely had a bit more revenue from, I guess, ILC Dover in third quarter. And just want to know what you're kind of penciling for fourth quarter from ILC Dover. And just maybe just within that address, the book to bill 0.97 for reported, 0.99 for core. Does that suggest there's a bit of book to build below 0.9 for acquisition? Maybe just unpack that for us. Thanks.
spk04: Yeah, Nigel, I'll try to answer all of those. So specifically in terms of PFT on the growth algorithm into Q4, a return to a positive organic, yes, that is the expectation, just to kind of state that one simply. In the context of the M&A contribution specifically in Q4, I think you'll see it comparable, maybe a touch lower than what you saw in Q3. But again, I wouldn't take that as anything in the context of any market trend or anything like that. Specifically with an ILC Dover, as Vicente said, I think the biopharma and the medical device business is very stable, continuing to see what you would expect to see, the normal growth and the sequential momentum you would expect. A lot of what you're seeing, and quite frankly, even now to your book-to-bill question, it really comes much more from the space side of the equation, where typically you see orders. They can be lumpy at times because they, quite frankly, are tied to larger, what I'll call platform-level kind of contracts. And then they tend to ship over a multi-quarter, multi-year timeframe. That's exactly what you saw in Q3. So you did see a book-to-bill that was below the fleet average. That was literally driven by... the space business. And the reality is in subsequent and future quarters, you'll see the exact inverse once you book some of those normal course contracts. Nothing that we would speak to that's outside the norm and actually very consistent with how that business operates. So again, we actually look, I would say it's very consistent. We're very pleased with the performance there. A little bit of noise, but I think the way you have characterized it and the numbers you're calling are fairly accurate.
spk01: Okay. And then just to be clear, are we still on track for 215, 220 guide for ILC?
spk04: Nigel, can you repeat the question?
spk01: Yeah, are we still on track for full-year contribution from ILC? I think it's 215, 220 is the range.
spk04: Yeah, I think that's in the right ballpark.
spk01: In the right ballpark. Okay, great. Thanks, Mike.
spk02: Your next question comes from the line of Joe Ritchie for Goldman Sachs. Your line is open. Thanks. Good morning, everybody.
spk14: Good morning, Joe. Hey, Vicente, can you just elaborate on what site readiness actually means? I know you referenced the Middle East. I'm assuming this is Brownfield Project and very separate than the like EPC discussion that we had earlier. And then also, and I know people are asking all these questions around, you know, orders and book to bill. I guess that there's a concern that, you know, the book to bill will kind of nosedive in the fourth quarter. And so just any kind of comments around what the expectation is for the book to bill, fully recognizing that typically in the second half of your year, it is typically below one.
spk11: Yeah, Joe, in terms of the site readiness, I mean, a pretty wide range in terms of as to the reason why In some cases, but I mean, it could be permits. It could be permits. Excuse me. It could be permitting in terms of Greenfields or even Brownfield about project expansion capacities. But it is basically permitting. It is a labor to be able to get some of the things on. In some cases, we're a piece of the entire process. So in many cases, the other pieces are not ready and we have to come in a certain time. It has to do with just the logistics and just getting a lot of these activities kind of put in place. In terms of the book to build, I mean, I think keep in mind that, you know, we said that we don't guide on orders, but we said that for the full year, we expect book to build to be approximately one. And, you know, what you can see kind of basically we are in that range. So we expect that book to bill to be, and we said the first half of the year is going to be usually above one. The second half of the year is usually less than one. And, you know, as we kind of came here in the third quarter, that kind of exactly, that's exactly what happened. And as we will see in the fourth quarter, that will be the same case. So we'll continue to expect that for the full year, we expect that book to bill to be, you know, squiggly approximately one. And that means basically organic orders should bode well in the fourth quarter.
spk14: Great. That's super helpful. And I guess just maybe just elaborate a little bit more on biopharma. Really nice to see that 20%. Typically, we thought of that as being very margin accretive to the business. And then we're hearing from others that there's places like, you know, radiopharm or theranostics that could see really good growth in the coming years. So just maybe elaborate on that piece of your business and specifically where you're seeing good momentum.
spk11: Yeah, I think the exciting piece is that, as we said before, is that this biopharma is very well focused, laser focused on approach in terms of high potency APIs. A lot of these high potency APIs, that is for the next generation of gene therapies, and whether you think about personalization of cancer treatment research or even as simply stated as these GLP-1s and drug weight reduction medicines. And there's now even new developments. I mean, I think so far a lot of these drugs have been kind of on a monoclonal antibodies, and now they're going into bimodal activity. So I think there's just a lot of good development, and for a lot of that development, you need these high-potency compounds. And in order to generate these high-potency compounds, you need to move the powder, and that's basically where we come in. We come in with great customization of powder handling and powder containment processes that are single-use in nature. And so I think our team continues to be very focused on accelerating growth, very focused on the early development on drugs. So I'll say, you know... I mean, I think there's just a lot of good growth momentum on that biopharma business.
spk14: Very helpful. Thank you, guys.
spk02: Your next question comes from Chris Snyder from Morgan Stanley. Your line is open.
spk12: Thank you. I want to follow up on the commentary around site readiness. You know, much of it, you know, appears tied to labor capacity and constraints there. So, you know, when you speak with customers, is there an expectation that that gets any better? You know, because I know unemployment, at least here in the U.S., continues to go higher, and it seems like demand for these projects and the activity is pushing higher. So it seems like that could remain a constraint.
spk11: Yeah, no, Chris, I mean, I think it varies country by country, for sure. But, yeah, I mean, I think that's exactly why we are smart about thinking about how You know we think about this gradual recovery and the momentum that because that you said it very well I mean labor will continue to be a constraint it's a constraint here in the US and continues to be a constraint in many other countries across the world and Many cases is that skilled labor is very needed for these very highly complicated.
spk12: Yeah Appreciate that and then maybe on on on China specifically. I know you said you're not really seeing any impact in the operating environment or from the stimulus of the early part of Q4. But I guess, do you think that the stimulus will have an impact on the economy there into 2025? Any way to think about the timing between when that could filter through? And just for all of us in the U.S., when you look at the policy measures, I guess, is there anything that stands out as potentially being impactful to Ingersoll?
spk11: Yeah, yeah, yeah. Great question there, Chris. You know, I think the most impactful one is that these latest stimulus is really around upgrading all the equipment. And you get a higher priority in many cases. And again, this is at the total national level, and then you got to go region by region. So, um but but the the high priority goes to those projects and those conversions that are going to deliver energy efficiency and clearly this is exactly the story that we have been uh saying all along in terms of what we are capable of doing on energy efficiency improvement so so i think that that is where we see that the stimulus could be impactful for against or run in terms of the timing it takes time i mean central government uh announces the stimulus and then it has to trickle down to the provinces and to the regions and that takes time uh now When I was in China just a week ago, did we hear more often and the teams were talking a lot about it? Yes. Have we seen it yet come to fruition? Not yet. But, you know, again, that's why we say it could bode well for 2025, and we'll see how kind of the fourth quarter goes from that perspective.
spk12: Thank you, Vicente. I appreciate that.
spk02: Thank you. Your next question comes from the line of Joe O'Day from Wells Fargo. The line is open. Hi, good morning.
spk13: Good morning. Vicente, could you talk about Ingersoll's kind of engagement in the timeline of a large project when we think about a growing pipeline of what can be multi-year projects, how to think about your involvement relative to when shovels go in the ground, sort of when you're engaged with the customer, when you get an order, when you ship it, relative to, say, shovels in the ground in a multi-year time frame?
spk11: Yeah, sure. Also, Joe, you know, from the early beginnings, we get involved. I mean, a lot of these large projects they have at the EPC side, they have what they call SMEs, subject matter experts. And they're subject matter experts on typical, specifically processing technology, like rotating component. And so we have really great relationship and contact with those educating what our products can do. When the project gets a decision, you know, the typical lead time is called 12 to 18 months between the order to the time of the shipment. And that could be you know, maybe 12 months later after the shovel goes into the ground. So it could be up to two years by the time that when the initial kind of dirt gets removed to the time the project gets to completion. But it varies. I mean, it clearly varies on the size of the project and the scope of the project. But our lead time could be anywhere between 12 to 18 months based on when the customer puts the order. and when the customer is ready for the site.
spk13: Got it. That's helpful. And then just wanted to come back to PST and some of the trends. I mean, when we look at the organic growth, the stacks, whether it's two-year, three-year, actually softened sequentially from Q2 to Q3. The guide suggests that those would improve sequentially from Q3 to Q4. It seems like within sort of the order framework as well and book-to-bill outlook that PST orders would sort of lead the growth in the fourth quarter. And so, you know, just looking for any color on lumpiness within the third quarter and how that's improving in the fourth quarter. Not sure if weather events were a factor, but any details there would be helpful.
spk04: Yeah, Joe, this is Zach. Maybe I'll start and I'll let Vicente add in as well. Would I point to any, I'll start with the latter part, any major weather-related things or anything of that nature? No, nothing of that note that I'd point to. You know, I think the piece that we are, continue to be encouraged about in terms of the, you know, in terms of PST is that we've now had two sequential quarters of positive year-over-year organic growth. And obviously, you know, I think we've kind of now fully consumed or comped a lot of those, what we'll call the legacy Ingersoll Rand Medical or Life Sciences headwinds that we've been talking about for a while. Have we seen a necessarily any meaningful recovery or anything there. No, not necessarily at this point in time. But I do think that that was what was cloudy, and I would say a lot of the historical comps. I think the good news, as we said in the prepared comments, was, one, I think the kind of more what I'll call industrial or book and ship continues to do nicely. It's been multiple quarters of that, I'd say, showing good trends. And then, remember, the PST business, it does also have some of the longer cycle type projects. that can create some of the noise that Vicente is speaking about. I think we talk about it much more prevalently in the ITS space, but there is some of that in PST. So I think the good news here is when you put that all together, particularly a couple of sequential quarters now of positive organic orders growth, now we expect to see that to start translating a little bit, and we do expect to see positive organic revenue growth specifically in Q4. Great. Thank you.
spk02: Your next question comes from David Russo from Evercore ISI. Your line is open.
spk10: Hi, thank you for the time. Just a quick question. The organic orders within ITS, I know page 18 provides sort of the all-in X currency, but just given the acquisitions, can you help us between compressors, vacuum, power tools, and other? The point four, I'm just trying to figure out how much would a bottoming China be you know, be as a boost to the organic orders. It's not that easy on page 18, just given those are all in X currency. Can you give those same splits organically to get to the organic order of 0.4 for the quarter?
spk04: Yeah, David, I'll give you, I think, probably the way to think about this, you know, at least a high level of A couple of components. Probably the two, I'd say, detractors, for lack of a better way to say that, when you think about the stack, and I'll do it by region, was clearly Asian Pacific, and clearly that's more of a China comment. And we would call that out in the, and there hasn't been, I would say, particularly China, the commentary, that's essentially all organic, right? There isn't a lot of M&A impacting that on the China side. That has obviously been the biggest negative comp, negative organic. meaningfully negative, that's what's driving that number closer to flattish. The power tools business, again, smaller piece of it. It was also, I'd say, below kind of the overall fleet average. So that's slightly bringing the numbers down. The more positive trends you're seeing are definitely in the... I'd say Americas is definitely kind of the leader of the pack comparatively. We also talked about that probably having one of the easier comps, comparatively speaking, on Q3, just given some of the timing of projects in terms of last year. And Europe, Middle East, India, Africa has kind of been in the middle. I'd say... India and the Middle East, frankly, places that Vicente and myself were in not too long ago, have been solid organic growth drivers. Western Europe has been a little bit of, I'd say, mixed in terms of some of the different regions. To give you the spectrum there, I would say the two biggest detractors definitely have been China and, to a lesser degree, power tools. America is comparatively stronger, and Europe kind of in the middle is probably the best way to think about it. And I wouldn't delineate dramatically between the product technologies. They tend to follow those regional trends fairly well.
spk10: I guess I ask directly, if China is, say at this point, down about 15% of ITS, maybe even slightly smaller, What were the organic orders ex-China, year-over-year in ITS, ex-China?
spk04: Yeah. David, we haven't given that, but what I will say here is would you be much more positive in that low single-digit realm? That's probably a fair statement.
spk10: Okay. So something like up three and China down 15. Something like that is sort of the math. Okay. Very helpful. Thank you.
spk02: Your next question comes from the line of Andrew Biscali from BNP Paribas. Your line is open.
spk04: Hey, good morning, everyone. Hey, good morning, Andrew. You know, something that caught my eye that was kind of interesting is your comment on some incremental activity in water treatment. You know, can you comment more on that? Is there more behind that? And, yeah, I guess what are you seeing in that market? Because it really seemed to accelerate quite a bit.
spk11: Yeah, so, yes, we do play very well in the water treatment. I mean, you saw the example of Dosatron, example that we gave here. But even within the PST, we have, you know, good technologies with CPEX, which is basically one of the market leaders for progressive cavity pumps in waste treatment facilities. You have Milton Roy, which is basically doing a lot of mixing and dosing as well for wastewater facilities. And even when you go into the ITS segment, we have technologies like blower technology that were one of the market leaders for creating the aeration in the wastewater facility. So, yes, the wastewater facilities and wastewater treatment processing has been an end market that we have put a lot of attention to. even including acquisitions. About a couple of years ago, we acquired a company called Everest in India that is a market leader for wastewater blower aeration. And again, if you think about India, only 30% of their water is treated. So great growth in that market. So yes, water and wastewater and water treatment are areas of opportunity for us to grow. Yeah, interesting.
spk04: You know, another comment I was hoping to get some color on You know, everyone's obviously trying to gauge your 2025. But what do you, you know, your free cash flow has been such a good story for a long time. Do you see incremental tailwinds as, you know, some of these projects, especially some that are kind of delayed here, really move forward? And maybe any other comment on other than fundamental sort of EBITDA margin expansion, you know, any other clicks and takes we should keep in mind as we you know, try to model out next year. And just to be clear, was that on the cash flow side of the equation? Was that the nature of the question? Yeah, cash flow. Yeah. It seems like you have incremental sort of tailwinds, especially with some of the pent-up projects. Yep. You know, I think, you know, maybe a couple of things in no necessarily particular order. Sure. You know, I think just frankly the business growth whether it be the projects or just the base business, absolutely. You know, I think working capital continues to be, you know, a huge focal point. I think we continue to make great strides in, you know, some of the more transactional pieces, accounts payable, accounts retrievable. I think inventory continues to be an opportunity to unlock that, you know, especially given the model that we have. I think a big piece that's, you know, probably, you know, we don't talk about it as much, but maybe a touch underappreciated is also the M&A side. generally speaking, the vast majority of M&A that we bring in, it frankly has a much higher working capital profile, just because quite frankly, a lot of them are smaller, privately held companies, probably less focused on working capital comparatively speaking to kind of where we are. And so as we bring them and integrate them in across the full spectrum of working capital, that's generally an opportunity. And then listen, we'll continue to continue to optimize, I'd say, what I'll call more of the blocking and tackling, you know, cash interest opportunity as we look forward, cash taxes, things of that nature. So I think there continue to be a lot of levers. And that being said, continue to be really pleased with where the teams have operated. You know, we've been in that 100% free cash flow conversion realm, and we will continue to, you know, target those levels, you know, with some of the opportunities that I mentioned. Yeah, great. Thank you.
spk02: Your next question comes from Nick Jones from Stifle. Your line is open.
spk03: Good morning, everyone. Good morning. Just a couple of questions back on the velocity of the MQLs through the funnel. Vicente, you said historically six to eight weeks and that that is materially longer now. Is it still getting longer or has it stabilized? Are things getting shorter? And if the major reasons are customer site readiness and insufficient EPC engineering capacity, these things will naturally move through that cycle. that process over time, is it really just time that we have to wait for the decision-making to accelerate again, or are there other conditions that need to exist?
spk11: Yeah, no, Nathan, sure. You know, I will say that the elongation, no material change in getting much longer, to be honest, but definitely clearly distinctly much more above that, you know, six- to eight-week conversion rates. In terms of the additional question, it is just time. I don't think... We don't see interest rates to be clearly... We never saw that being the impact for any of these to be kind of the driver. You know, we made a commentary about here how elections, you know, really not the dramatic change. Could that maybe accelerate as we kind of finalize and get these over with next week, potentially? but not something that we're counting on. But yeah, it's just mainly time here in this case.
spk03: You guys have a little bit more visibility than we're going to have from the outside into those kinds of things. Is there an expectation or do you have, you know, intelligence into the markets that would suggest, you know, kind of when that MQL lead time might start to shrink and these things might start to move forward?
spk11: I mean, I would tell you, Nathan, it varies dramatically country by country depending on situations and depending on customer projects. So I would say, do we have intelligence on a lot of the projects and a lot of data? Yes. Are we going to verbalize that externally? Likely not. But yes, we do know very well.
spk03: Fair enough. And you made a comment that things are brooding well for 4Q organic orders. Could you just elaborate on that a little bit?
spk04: Yeah, I think that the comment was, you know, I think it was positioned in the kind of the math around the book to bill. And, you know, if you kind of run the math out and, you know, now with three quarters behind us and, you know, you kind of know all the variables, would it imply kind of something in the maybe low single digit or organic growth realm for orders? That's kind of what the math would imply. And you'll still kind of be around that one time book to bill. You know, I think to Vicente's point and kind of what you've seen, you know, like I said, you've seen two quarters of good sequential, you know, good year-over-year orders, organic orders growth in PST. You did see ITS return back to positive organic realm in Q3. So, again, what we'll say is the leading indicator, the general market continues to remain, you know, relatively stable and relatively healthy. So, we're encouraged kind of as we, you know, as we kind of move here into the fourth quarter.
spk03: Thanks very much for taking my questions. Sure, Benjamin. Thanks.
spk02: There are no further questions at this time, so I'd like to hand the call back to Vicente Villanueva for closing remarks.
spk11: Yeah, thank you. I'll say that my last remark will be, again, a big thank you to our teams for another great quarter and the fact that our economic growth engine is working very well to deliver very good results, even despite microeconomic environments. It's very exciting to see. So, again, thanks, everyone, for the interest and look forward to speaking with you many times. So, thank you.
spk02: That does conclude our conference for today. Thank you for participating. We're now all just connect.
Disclaimer